Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
BMC Neurol ; 17(1): 150, 2017 Aug 07.
Artigo em Inglês | MEDLINE | ID: mdl-28784108

RESUMO

BACKGROUND: Evidence on the use of fingolimod in real-world clinical practice and data on patient-reported health-related quality of life (HRQoL) in countries such as the Middle East are sparse. The Prospective Evaluation of Treatment with Fingolimod for Multiple Sclerosis (PERFORMS) study assessed HRQoL and effectiveness and safety of fingolimod in patients with relapsing-remitting multiples sclerosis (RRMS), primarily in Middle Eastern countries. METHODS: This 12-month, observational, multicentre, prospective, real-world study was conducted in patients with RRMS who initiated fingolimod or another approved disease-modifying treatment (DMT) within 4 weeks before study entry. Patients were enrolled in a 2:1 ratio to obtain more data in fingolimod and parallel in other DMTs cohort by physicians during routine medical care. Key study outcomes included HRQoL assessed using MS International QoL (MusiQoL), MS relapses and disability. Safety was assessed throughout the study period. Due to the observational nature of the study, no neuroimaging assessments were mandated and central reading was not performed. RESULTS: Of 249 enrolled patients, 247 were included in the analysis (fingolimod cohort 172; other DMTs cohort 75). Overall, the mean age of patients was 36.5 years, 64.4% were women and ~90% were Caucasians. At baseline, mean MS duration since diagnosis was 7.2 years in the fingolimod and 4.8 years in the other DMTs cohorts. Overall, mean changes in MusiQoL index scores were -2.1 in the fingolimod cohort and -0.7 in the other DMTs cohort at Month 12, but improvement was not significant vs. baseline in both cohorts. Proportion of relapse-free patients increased significantly during the study vs. 0-12 months before the study in the fingolimod cohort (80.2% vs. 24.4%; p < 0.0001). Proportion of patients free from disability progression was 86.5% in the fingolimod cohort. The incidences of AEs were 59.9% and 50.6% in the fingolimod and other DMTs cohorts, respectively. First-dose monitoring of fingolimod observed no cases of symptomatic bradyarrhythmia. Three cases of bradycardia were reported in the fingolimod cohort: one after the first dose and two during the study. No cases of macular oedema were observed during the study. CONCLUSIONS: Fingolimod treatment maintained QoL over 12 months and was effective in reducing relapse rate and disability progression. No new safety findings were observed in this real-world observational study in Middle Eastern countries.


Assuntos
Cloridrato de Fingolimode/uso terapêutico , Imunossupressores/uso terapêutico , Esclerose Múltipla Recidivante-Remitente/tratamento farmacológico , Adolescente , Adulto , Idoso , Estudos de Coortes , Pessoas com Deficiência , Progressão da Doença , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Oriente Médio , Estudos Prospectivos , Qualidade de Vida , Recidiva , Adulto Jovem
2.
Neurology ; 84(9): 872-9, 2015 Mar 03.
Artigo em Inglês | MEDLINE | ID: mdl-25636714

RESUMO

OBJECTIVE: To evaluate immune responses in fingolimod-treated patients with multiple sclerosis (MS) against influenza vaccine (to test for responses against anticipated novel antigens in seronegative patients) and recall (tetanus toxoid [TT] booster dose) antigens. METHODS: This was a blinded, randomized, multicenter, placebo-controlled study. Patients aged 18 to 55 years with relapsing MS were randomized (2:1) to fingolimod 0.5 mg or placebo for 12 weeks. At week 6, patients received seasonal influenza vaccine (containing antigens of California, Perth, and Brisbane virus strains) and TT booster dose. Antibody titers against influenza and TT were estimated at baseline (prevaccination) and 3 and 6 weeks postvaccination. The primary efficacy variable was responder rate (proportion of patients showing seroconversion or significant increase [≥4-fold] in antibody titers against at least one influenza virus strain) at 3 weeks postvaccination and vs placebo. RESULTS: Of 138 randomized patients (fingolimod 95, placebo 43), 136 completed the study (2 discontinued in fingolimod group). The responder rates (odds ratio; 95% confidence interval) for influenza vaccine (fingolimod vs placebo) were 54% vs 85% (0.21; 0.08-0.54) at 3 weeks and 43% vs 75% (0.25; 0.11-0.57) at 6 weeks postvaccination. For TT, responder rates were 40% vs 61% (0.43; 0.20-0.92) at 3 weeks and 38% vs 49% (0.62; 0.29-1.33) at 6 weeks postvaccination. Adverse events were reported in 86.3% and 79.1% of patients receiving fingolimod and placebo, respectively. CONCLUSION: Most fingolimod-treated patients with MS were able to mount immune responses against novel and recall antigens and the majority met regulatory criteria indicating seroprotection. However, response rates were reduced compared with placebo-treated patients. This should be kept in mind when vaccinating patients on fingolimod. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that in some patients with MS receiving immunizations, concurrent fingolimod treatment in comparison to placebo decreases vaccination-induced immune responses.


Assuntos
Imunossupressores/uso terapêutico , Vacinas contra Influenza/uso terapêutico , Esclerose Múltipla/tratamento farmacológico , Propilenoglicóis/uso terapêutico , Esfingosina/análogos & derivados , Vacinação , Adolescente , Adulto , Método Duplo-Cego , Feminino , Cloridrato de Fingolimode , Humanos , Imunossupressores/imunologia , Vacinas contra Influenza/imunologia , Masculino , Pessoa de Meia-Idade , Esclerose Múltipla/imunologia , Propilenoglicóis/imunologia , Esfingosina/imunologia , Esfingosina/uso terapêutico , Resultado do Tratamento , Vacinação/métodos , Adulto Jovem
3.
J Neurol ; 261(2): 267-76, 2014 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-24221641

RESUMO

The aim of this study was to evaluate short-term safety and tolerability of fingolimod in a real-world population with relapsing multiple sclerosis, focusing on cardiac safety during treatment initiation. Patients received fingolimod 0.5 mg once daily for four months. Patients excluded from the pivotal studies with certain pre-existing cardiac conditions or baseline cardiac findings (PCCs), and those receiving beta blockers (BBs) and/or calcium channel blockers (CCBs), were eligible. Heart rate (HR) and electrical conduction events were monitored using ambulatory electrocardiography for at least 6 h after the first dose. Of 2,417 enrolled patients, 2,282 (94.4 %) completed the study. Fingolimod initiation was associated with a transient, mostly asymptomatic decrease in HR. Bradycardia adverse events occurred in 0.6 % of patients and were more frequent in individuals receiving BBs/CCBs (3.3 %) than in other patient subgroups (0.5-1.4 %); most events were asymptomatic, and all patients recovered without pharmacological intervention. In the 6 h post-dose, the incidences of Mobitz type I second-degree atrioventricular block (AVB) and 2:1 AVB were higher in patients with PCCs (4.1 and 2.0 %, respectively) than in those without (0.9 and 0.3 %, respectively); at pre-dose screening, patients with PCCs had the same incidence of Mobitz type I second-degree AVB (4.1 %) and a slightly lower incidence of 2:1 AVB (0.7 %) than 6 h post-dose. All recorded conduction abnormalities were asymptomatic. This study adds to the evidence showing that cardiac effects during fingolimod initiation remain consistent with those known from previous, controlled studies, even if patients with PCCs are included.


Assuntos
Cardiopatias/epidemiologia , Imunossupressores/efeitos adversos , Imunossupressores/uso terapêutico , Esclerose Múltipla Recidivante-Remitente/tratamento farmacológico , Propilenoglicóis/efeitos adversos , Propilenoglicóis/uso terapêutico , Esfingosina/análogos & derivados , Adolescente , Adulto , Fatores Etários , Idoso , Bradicardia/induzido quimicamente , Bradicardia/fisiopatologia , Avaliação da Deficiência , Eletrocardiografia , Determinação de Ponto Final , Feminino , Cloridrato de Fingolimode , Sistema de Condução Cardíaco/fisiologia , Cardiopatias/etiologia , Frequência Cardíaca/efeitos dos fármacos , Humanos , Masculino , Pessoa de Meia-Idade , Esclerose Múltipla Recidivante-Remitente/complicações , Segurança do Paciente , Esfingosina/efeitos adversos , Esfingosina/uso terapêutico , Resultado do Tratamento , Adulto Jovem
4.
J Clin Hypertens (Greenwich) ; 12(12): 917-26, 2010 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-21122057

RESUMO

Patients with stage 2 hypertension (systolic blood pressure [SBP] ≥160mm Hg and/or diastolic blood pressure [DBP] ≥100mm Hg) are at high cardiovascular risk and require intensive blood pressure (BP)-lowering therapy. This randomized double-blind study is the first prospective trial specifically designed to evaluate the direct renin inhibitor aliskiren in patients with a mean sitting SBP ≥160 mm Hg and <180mm Hg (the lower ranges of stage 2 systolic hypertension). After a 2- to 4-week washout period, 688 patients were randomized to once-daily aliskiren/hydrochlorothiazide (HCT) 150/12.5mg or aliskiren 150mg for 1 week and then double the doses for 11 weeks. Baseline BP was 167.1/95.0mm Hg. At week 12, both aliskiren/HCT and aliskiren provided substantial BP reductions from baseline (30.0/12.6 mm Hg and 20.3/8.2 mm Hg, respectively). Aliskiren/HCT lowered BP significantly more than aliskiren (least-squares mean between-treatment differences [95% confidence interval] were -9.7 [-12.0 to -7.4] for SBP and -4.5 [-5.8 to -3.2] for DBP; both P<.0001). Similar BP reductions were seen in the subgroups of patients with isolated systolic hypertension and obesity. Aliskiren, with or without HCT, provides clinically significant BP reductions and may therefore be an effective treatment option in patients with stage 2 hypertension.


Assuntos
Amidas/uso terapêutico , Anti-Hipertensivos/uso terapêutico , Fumaratos/uso terapêutico , Hidroclorotiazida/uso terapêutico , Hipertensão/tratamento farmacológico , Índice de Gravidade de Doença , Idoso , Amidas/efeitos adversos , Amidas/farmacologia , Anti-Hipertensivos/efeitos adversos , Anti-Hipertensivos/farmacologia , Pressão Sanguínea/efeitos dos fármacos , Pressão Sanguínea/fisiologia , Relação Dose-Resposta a Droga , Método Duplo-Cego , Quimioterapia Combinada , Feminino , Fumaratos/efeitos adversos , Fumaratos/farmacologia , Humanos , Hidroclorotiazida/efeitos adversos , Hidroclorotiazida/farmacologia , Hipertensão/fisiopatologia , Masculino , Pessoa de Meia-Idade , Resultado do Tratamento
5.
Chemosphere ; 67(6): 1229-35, 2007 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-17182078

RESUMO

Sludge from common effluent treatment plant (CETP) receiving effluents from textile industries at Mandia Road, Pali, was analyzed to assess the level of mutagenicity. Mutagenicity assay using Salmonella typhimurium tester strains TA 98 and TA 100 gave positive results, thus suggesting presence of genotoxic contaminants in the samples investigated. Further, mutagenic activity of chemical sludge was found to be lesser than that of biological sludge. This result is very surprising and unexpected as it is indicating that some mutagenic compounds are either being formed or certain promutagenic compounds are being converted into stable mutagenic metabolites during the biological treatment of the wastewater effluents. There have been no previous reports giving similar or contrary results. Most of the previous studies have reported effects of single combined sludge.


Assuntos
Resíduos Industriais , Mutagênicos/toxicidade , Salmonella typhimurium/genética , Esgotos , Poluentes Químicos da Água/toxicidade , Índia , Testes de Mutagenicidade , Eliminação de Resíduos Líquidos , Poluição da Água/prevenção & controle
6.
Ecotoxicol Environ Saf ; 61(1): 105-13, 2005 May.
Artigo em Inglês | MEDLINE | ID: mdl-15814316

RESUMO

Sanganer town, district Jaipur (Rajasthan, India), is famous worldwide for its dyeing and printing industries. There are about 400 industries involved in textile printing processes, which discharge effluents into nearby ponds and drains, without any treatment. These effluents contain highly toxic dyes, bleaching agents, salts, acids, and alkalis. Heavy metals like cadmium, copper, zinc, chromium, and iron are also found in the dye effluents. Textile workers are exposed to such waters with no control over the length and frequency of exposure. Further, as the untreated effluents are discharged into the environment they can cause severe contamination of surface and underground water. Environmental pollution caused by such textile effluents results in adverse effects on flora, fauna, and the general health of not only the textile workers, but also the residents of Sanganer town. Therefore, to assess the possible genotoxic health risk and environmental genotoxicity due to the textile industry effluents, this study was carried out using the Ames Salmonella/microsome mutagenicity assay. The results clearly indicate that the effluents and the surface water of Amani Shah drainage have high mutagenic activity. Further, the drainage water and the dry bed of the drainage (during summer months) are not fit for agricultural or other recreational purposes. A low level of mutagenicity in the underground water of Sanganer again emphasizes the grave pollution problem existing in the area. Multiple post hoc comparison tests (LSD, Tukey's) were used for comparison of sample site, dose, and length of exposure. Quadratic Model was found to adequately fit the observed data.


Assuntos
Corantes/toxicidade , Resíduos Industriais/efeitos adversos , Mutagênicos/toxicidade , Indústria Têxtil , Animais , Água Doce/análise , Técnicas In Vitro , Índia , Microssomos Hepáticos/metabolismo , Testes de Mutagenicidade , Ratos , Salmonella typhimurium/efeitos dos fármacos , Salmonella typhimurium/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...